Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors

Core Insights - Henrik Keller has resigned from the Board of Directors of Nordicus Partners Corporation, leading to an expansion of the Board from three to five members with the appointments of Torben Jensen, Kim T. Mücke, and Andrew J. Ritter [1][2] Group 1: Board Changes - The Board of Directors has increased from three to five members following the resignation of Henrik Keller [1] - Torben Jensen, a major shareholder, will assist in funding Nordicus and its subsidiaries [2] - Kim T. Mücke will serve as chairman of the Audit Committee, bringing extensive experience from Deloitte [2][4] - Andrew J. Ritter, an experienced CEO in the pharma space, will aid in corporate finance and strategic relationships [2][5] Group 2: New Board Members' Backgrounds - Torben Jensen has over 35 years of experience in finance and has previously held CEO and Chairman positions in listed companies [3] - Kim T. Mücke is a state-authorized public accountant with a background in financial reporting and risk management, previously a partner at Deloitte [4] - Andrew J. Ritter has a strong background in the biotech and MedTech sectors, having served as CEO in multiple companies [5] Group 3: Company Overview - Nordicus Partners Corporation is a publicly traded business accelerator and holding company focused on Nordic life sciences companies [6] - The company has successfully acquired 100% of two Danish preclinical-stage biotech companies, Orocidin A/S and Bio-Convert A/S, in 2024 [6]